TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1430130

Group type: EXPERIMENTAL
Intervention: Gonadotrophin releasing hormone agonist (GnRHa) in the midluteal phase coupled with follicular phase administration of human menopausal gonadotrophin
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 28
Study: 3908501

Group type: EXPERIMENTAL
Intervention: carteolol 5 mg
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: carteolol 20 mg
Number of subjects: 35

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 35
Study: 2424123

Group type: EXPERIMENTAL
Intervention: Penicillin G
Number of subjects: 113

Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 113
Study: 31751183

Group type: EXPERIMENTAL
Intervention: Dexamethasone (4 mg bid)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study: 30047286

Group type: EXPERIMENTAL
Intervention: Coencapsulated TDF/FTC with the Proteus ingestible sensor
Number of subjects: 24

Group type: COMPARATOR
Intervention: Unencapsulated TDF/FTC
Number of subjects: 24
Study: 28741804

Group type: EXPERIMENTAL
Intervention: Whey protein group (1.2 g/kg per day protein diet + 25% additional whey protein supplement)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (1.2 g/kg per day protein diet without additional whey protein supplementation)
Number of subjects: 36
Study: 26446265

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 200
Study: 23130909

Group type: EXPERIMENTAL
Intervention: Intravenous iron sucrose (400 mg) plus folic acid (600 µg)
Number of subjects: 271

Group type: COMPARATOR
Intervention: Oral iron (ferrous sulfate with folic acid)
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Both intravenous iron and oral iron
Number of subjects: 271
Study: 21508850

Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other antipsychotics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 0
Study: 18311683

Group type: EXPERIMENTAL
Intervention: Active high-frequency rTMS over the left cortex
Number of subjects: 45

Group type: COMPARATOR
Intervention: Sham TMS
Number of subjects: 45
Study: 17133559

Group type: EXPERIMENTAL
Intervention: Infliximab (3 mg/kg)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Infliximab (3 mg/kg) with methotrexate
Number of subjects: 106
Study: 14535876

Group type: COMPARATOR
Intervention: Empirical treatment with ranitidine bismuth citrate, 400 mg b.d., tinidazole, 500 mg b.d., and clarithromycin, 500 mg b.d.
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Antimicrobial sensitivity testing-based treatment with ranitidine bismuth citrate, 400 mg b.d., tinidazole, 500 mg b.d., and clarithromycin, 500 mg b.d.
Number of subjects: 242

Group type: COMPARATOR
Intervention: Omeprazole, 20 mg b.d., clarithromycin, 500 mg b.d., and amoxicillin, 1 g b.d.
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate, 400 mg b.d., tinidazole, 500 mg b.d., and clarithromycin, 500 mg b.d.
Number of subjects: 242
Study: 10746516

Group type: EXPERIMENTAL
Intervention: 200 mg magnesium + 50 mg vitamin B6
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 9545899

Group type: EXPERIMENTAL
Intervention: 0.06% chlorhexidine irrigation using a powered oral irrigator (Water Pik)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.12% chlorhexidine gluconate rinsing once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison between 0.06% chlorhexidine irrigation and 0.12% chlorhexidine rinsing
Number of subjects: 0
Study: 1408551

Group type: EXPERIMENTAL
Intervention: Planned bottle group (one bottle daily between the second and sixth weeks postpartum)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Total breast-feeding group (avoiding bottles during the same period)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Planned bottle group
Number of subjects: 121

Group type: COMPARATOR
Intervention: Total breast-feeding group
Number of subjects: 121
Study: 3930197

Group type: EXPERIMENTAL
Intervention: Nitroderm TTS 10
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Nitradisc 10
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Deponit 10
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Nitro‐Pflaster‐ratiopharm 10
Number of subjects: 8
Study: 30528222

Group type: EXPERIMENTAL
Intervention: Cabozantinib 60mg once daily orally
Number of subjects: 119

Group type: COMPARATOR
Intervention: Mitoxantrone 12mg/m2 every 3 weeks plus prednisone 5mg twice daily orally
Number of subjects: 119
Study: 28903131

Group type: EXPERIMENTAL
Intervention: Positive MGMT expression
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: Fluorouracil-based adjuvant chemotherapy in MGMT-positive patients
Number of subjects: 445
Study: 26700279

Group type: EXPERIMENTAL
Intervention: Multidisciplinary Multistep Medication Review (3MR)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group (usual care by pharmacist and general practitioner)
Number of subjects: 160
Study: 24034941

Group type: EXPERIMENTAL
Intervention: Menstrual pictogram (SAP‐c version)
Number of subjects: 12
Study: 21346608

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reserpine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19698734

Group type: EXPERIMENTAL
Intervention: GVG (1 g/day increased to 5 g/day)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: GVG
Number of subjects: 17
Study: 17645444

Group type: EXPERIMENTAL
Intervention: Sildenafil treatment
Number of subjects: 2573
Study: 15025222

Group type: EXPERIMENTAL
Intervention: Low-dose doxycycline (20 mg) b.i.d. for 3 months plus scaling and root planing (SRP)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo capsules b.i.d. for 3 months plus scaling and root planing (SRP)
Number of subjects: 30
Study: 11597949

Group type: EXPERIMENTAL
Intervention: Vitamin E at 300 mg/d during dinner (group B)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Vitamin E at 300 mg/d on an empty stomach (group A)
Number of subjects: 20
Study: 10518852

Group type: EXPERIMENTAL
Intervention: Herbal Mouth and Gum Therapy
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Peridex
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Listerine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Water control
Number of subjects: 20
Study: 8624429

Group type: EXPERIMENTAL
Intervention: Nafarelin acetate 600 micrograms/daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: D-Trp6-LHRH 0.5 mg/daily
Number of subjects: 40
Study: 2722135

Group type: EXPERIMENTAL
Intervention: Oral fructose load
Number of subjects: 12

Group type: COMPARATOR
Intervention: Oral glucose load
Number of subjects: 12
Study: 141471

Group type: EXPERIMENTAL
Intervention: Aerosolized atropine sulfate (1 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: SCH 1000 (40 microgram and 80 microgram)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31733926

Group type: EXPERIMENTAL
Intervention: HLA-DQB1, -DQA1, -DPB1, and -DPA1 genotyping
Number of subjects: 1064

Group type: EXPERIMENTAL
Intervention: HLA-DPB1 matching
Number of subjects: 1064
Study: 31871257

Group type: EXPERIMENTAL
Intervention: Dry cupping therapy application with two suctions, performed once a week for 8 weeks.
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo dry cupping therapy, performed once a week for 8 weeks.
Number of subjects: 90
Study: 28558502

Group type: EXPERIMENTAL
Intervention: Ranger drug‐coated balloon (DCB)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control (uncoated balloon angioplasty)
Number of subjects: 105
Study: 25645167

Group type: EXPERIMENTAL
Intervention: Behavioral Activation (BA)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 43
Study: 23986166

Group type: EXPERIMENTAL
Intervention: Test formula containing Ambophenol, Neurosensine, and La Roche-Posay thermal spring water applied twice daily for 4 weeks as monotherapy
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Test formula applied twice daily for 8 weeks as adjunctive therapy
Number of subjects: 102

Group type: COMPARATOR
Intervention: Vehicle control applied twice daily for 8 weeks
Number of subjects: 102
Study: 21074790

Group type: EXPERIMENTAL
Intervention: 0.1 mg desmopressin orally at bedtime
Number of subjects: 115

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study: 20120751

Group type: EXPERIMENTAL
Intervention: Non-opioid fast-track anesthesia (bupivacaine-ketamine)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Opioid fast-track anesthesia (bupivacaine-fentanyl)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Conventional general anesthetic technique (Control)
Number of subjects: 75
Study: 18051713

Group type: EXPERIMENTAL
Intervention: xMAP technology
Number of subjects: 1061

Group type: COMPARATOR
Intervention: hc2
Number of subjects: 1061
Study: 15196307

Group type: EXPERIMENTAL
Intervention: Training module and administration of the guideline (Arm 1)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Administration of guideline without training (Arm 2)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Current practice (Control Arm 3)
Number of subjects: 252
Study: 11758228

Group type: EXPERIMENTAL
Intervention: Thrombopoietin (Tpo) levels in CITP patients
Number of subjects: 33

Group type: COMPARATOR
Intervention: Thrombopoietin (Tpo) levels in aplastic anemia (AA) patients
Number of subjects: 33

Group type: COMPARATOR
Intervention: Thrombopoietin (Tpo) levels in acute myelogenous leukemia (AML) patients
Number of subjects: 33

Group type: COMPARATOR
Intervention: Reticulated platelet count (RPC) in AA and AML patients
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Reticulated platelet percentage (RP%) in CITP and AML patients
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Tpo levels in CITP patients with glucocorticoid therapy response
Number of subjects: 33
Study: 9127923

Group type: EXPERIMENTAL
Intervention: Epidural blockade with 20 ml of 0.25% bupivacaine
Number of subjects: 40

Group type: COMPARATOR
Intervention: No epidural blockade
Number of subjects: 40
Study: 8179049

Group type: EXPERIMENTAL
Intervention: Individually computer‐tailored nutrition messages
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nontailored nutrition information based on the 1990 Dietary Guidelines for Americans
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 3284457

Group type: EXPERIMENTAL
Intervention: Ceftazidime (30 mg/kg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Cefoperazone (30 mg/kg)
Number of subjects: 6
Study: 29570601

Group type: EXPERIMENTAL
Intervention: Compression Garments (CG)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 16
Study: 28601820

Group type: EXPERIMENTAL
Intervention: Innominate artery cannulation
Number of subjects: 110

Group type: COMPARATOR
Intervention: Axillary artery cannulation
Number of subjects: 110
Study: 25637271

Group type: EXPERIMENTAL
Intervention: Energy device (ultrasonically activated device and bipolar vessel sealing device)
Number of subjects: 212

Group type: COMPARATOR
Intervention: No energy device (control group)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Energy device
Number of subjects: 212
Study: 23216423

Group type: EXPERIMENTAL
Intervention: Betrixaban 80 mg
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Betrixaban 140 mg
Number of subjects: 96

Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg (positive control)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 21134018

Group type: EXPERIMENTAL
Intervention: Movie with alcohol portrayal
Number of subjects: 122

Group type: COMPARATOR
Intervention: Movie with no alcohol portrayal
Number of subjects: 122
Study: 19238715

Group type: EXPERIMENTAL
Intervention: Kangaroo Care (KC) for 10 min before the injection and during the procedure
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 100
Study: 16572350

Group type: EXPERIMENTAL
Intervention: Norepinephrine infusion (NE)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Deep breathing
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Head‐up tilt
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Child‐Pugh scale
Number of subjects: 25
Study: 12944340

Group type: EXPERIMENTAL
Intervention: Clomipramine (150 mg/day)
Number of subjects: 292

Group type: COMPARATOR
Intervention: Citalopram (40 mg/day)
Number of subjects: 292

Group type: COMPARATOR
Intervention: Paroxetine (30 mg/day)
Number of subjects: 292

Group type: COMPARATOR
Intervention: Moclobemide (400 mg/day)
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Clomipramine plasma concentrations
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Posttreatment Hamilton depression scale scores
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Dropout rates and side effects
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Therapeutic effects of treatment
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Relationship between plasma concentrations, gender, and therapeutic outcome
Number of subjects: 292
Study: 10958603

Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 55

Group type: COMPARATOR
Intervention: No atropine (Control)
Number of subjects: 55
Study: 9211675

Group type: EXPERIMENTAL
Intervention: 2 g of elemental calcium
Number of subjects: 4589

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4589
Study: 7999735

Group type: EXPERIMENTAL
Intervention: Intermaxillary fixation (IMF)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Miniplate osteosynthesis
Number of subjects: 22
Study: 2973171

Group type: EXPERIMENTAL
Intervention: Megace
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Megace plus DES
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stilphostrol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Streptozotocin
Number of subjects: 0
Study: 31735141

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 2325

Group type: EXPERIMENTAL
Intervention: Blend sign
Number of subjects: 2325

Group type: EXPERIMENTAL
Intervention: Black hole sign
Number of subjects: 2325

Group type: EXPERIMENTAL
Intervention: Hypodensities
Number of subjects: 2325

Group type: EXPERIMENTAL
Intervention: Island sign
Number of subjects: 2325
Study: 31097181

Group type: EXPERIMENTAL
Intervention: Pilates training
Number of subjects: 110
Study: 28682183

Group type: EXPERIMENTAL
Intervention: Low-fat Dietary Modification (DM), N = 19,540, average duration 8.1 years
Number of subjects: 48834

Group type: EXPERIMENTAL
Intervention: Aspirin use at baseline
Number of subjects: 48834

Group type: COMPARATOR
Intervention: Comparison group, N = 29,294
Number of subjects: 48834
Study: 25956949

Group type: EXPERIMENTAL
Intervention: HDF (Haemodiafiltration)
Number of subjects: 51

Group type: COMPARATOR
Intervention: HD (High-flux haemodialysis)
Number of subjects: 51
Study: 22354337

Group type: EXPERIMENTAL
Intervention: Self-video task
Number of subjects: 60

Group type: COMPARATOR
Intervention: Regular practical tutoring
Number of subjects: 60
Study: 21302036

Group type: EXPERIMENTAL
Intervention: NIPRD-AM1 (250 mg×2) with metronidazole (200 mg×2)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Metronidazole (200 mg×2) alone
Number of subjects: 11
Study: 19758257

Group type: EXPERIMENTAL
Intervention: 0.002% chlorhexidine for 15 s
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.002% chlorhexidine for 60 s
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.02% chlorhexidine for 60 s
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine for 60 s
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine for 60 s
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 4% chlorhexidine for 60 s
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine for 15 s
Number of subjects: 0

Group type: COMPARATOR
Intervention: Water
Number of subjects: 0
Study: 17009630

Group type: EXPERIMENTAL
Intervention: GnRH analogue treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated (control group)
Number of subjects: 0
Study: 12657164

Group type: EXPERIMENTAL
Intervention: Standard of care plus SU5416 (VEGF receptor tyrosine kinase inhibitor)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Standard of care chemotherapy
Number of subjects: 23
Study: 10933368

Group type: EXPERIMENTAL
Intervention: Estrogen use
Number of subjects: 1134

Group type: COMPARATOR
Intervention: Estrogen nonuse (Control)
Number of subjects: 1134
Study: 8623068

Group type: EXPERIMENTAL
Intervention: Measurement by 14 examiners using three different instruments
Number of subjects: 18
Study: 2169702

Group type: EXPERIMENTAL
Intervention: Oat bran
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Rice bran
Number of subjects: 24

Group type: COMPARATOR
Intervention: Wheat bran
Number of subjects: 24
Study: 6454395

Group type: EXPERIMENTAL
Intervention: Oral treatment with 13‐cis retinoic acid
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 18
Study: 31734573

Group type: EXPERIMENTAL
Intervention: Computerized interpretation bias modification (CBM‐I) training, four sessions over a 2-week period
Number of subjects: 0

Group type: COMPARATOR
Intervention: Computerized 'sham' training (control condition), four sessions over a 2-week period
Number of subjects: 0
Study: 30910894

Group type: EXPERIMENTAL
Intervention: DSTA4637S (5, 15, 50, 100, and 150 mg/kg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 28328705

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) at 650 nm, administered every other day for 17 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham treatment (control group)
Number of subjects: 0
Study: 25829373

Group type: EXPERIMENTAL
Intervention: Intravenous fosfomycin (4 g/6 h)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Meropenem (1 g/8 h)
Number of subjects: 0
Study: 23949025

Group type: EXPERIMENTAL
Intervention: Robot-assisted therapy with sequential target presentation
Number of subjects: 31

Group type: COMPARATOR
Intervention: Robot-assisted therapy with random target presentation
Number of subjects: 31
Study: 21120558

Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Lornoxicam 8 mg
Number of subjects: 16
Study: 19549186

Group type: EXPERIMENTAL
Intervention: BoNT‐A (50 U)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study: 17655805

Group type: EXPERIMENTAL
Intervention: rTMS (10 sessions of daily stimulation over the left dorsolateral prefrontal cortex)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: rTMS (20 sessions of daily stimulation over the left dorsolateral prefrontal cortex)
Number of subjects: 18

Group type: COMPARATOR
Intervention: sham rTMS (10 sessions)
Number of subjects: 18

Group type: COMPARATOR
Intervention: sham rTMS (20 sessions)
Number of subjects: 18
Study: 15175560

Group type: EXPERIMENTAL
Intervention: Terbutaline (large intravenous doses)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 11355926

Group type: EXPERIMENTAL
Intervention: Intensive consolidation treatment with high-dose Ara-C
Number of subjects: 0

Group type: COMPARATOR
Intervention: Allogeneic or autologous transplantation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard risk patients
Number of subjects: 0
Study: 9935255

Group type: EXPERIMENTAL
Intervention: Trovafloxacin (200 mg) with Morphine (0.15 mg/kg)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Morphine (0.15 mg/kg)
Number of subjects: 19
Study: 9052509

Group type: EXPERIMENTAL
Intervention: Omeprazole therapy for eight weeks
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (moderate GER disease)
Number of subjects: 22
Study: 2476613

Group type: EXPERIMENTAL
Intervention: Controlled-release isosorbide-5-mononitrate (ISMN-CR) 60 mg once daily
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Controlled-release isosorbide-5-mononitrate (ISMN-CR) 60 mg twice daily
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin (NTG)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 786379

Group type: EXPERIMENTAL
Intervention: Oral papaverine (300 mg b.i.d.)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 21
Study: 31120988

Group type: EXPERIMENTAL
Intervention: 200 ppm NaOCl
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 9 ppm aqueous-O3
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 400 ppm PAA
Number of subjects: 14

Group type: COMPARATOR
Intervention: Positive control (contaminated with feces-Salmonella mixture, not exposed to disinfectants)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Negative control (laboratory blank, inoculated only with sterile water)
Number of subjects: 14
Study: 27966225

Group type: COMPARATOR
Intervention: Control (CONT)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Propranolol (PROP)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate (GLYC)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Propranolol and Glycopyrrolate (PROP+GLYC)
Number of subjects: 7
Study: 25997044

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) training
Number of subjects: 84

Group type: COMPARATOR
Intervention: Blended Learning (BL)
Number of subjects: 84
Study: 23969029

Group type: EXPERIMENTAL
Intervention: Pedometer-based, Internet-mediated intervention (n=111)
Number of subjects: 229

Group type: COMPARATOR
Intervention: Usual care (n=118)
Number of subjects: 229
Study: 21471765

Group type: EXPERIMENTAL
Intervention: CONNECT intervention (n = 39)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Usual care (control group, n = 36)
Number of subjects: 75
Study: 19308305

Group type: EXPERIMENTAL
Intervention: Natalizumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Natalizumab in treatment-naive patients with highly active disease
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Natalizumab in patients with highly active disease despite IFNbeta-1a treatment
Number of subjects: 0
Study: 16908773

Group type: EXPERIMENTAL
Intervention: Endeavor zotarolimus-eluting phosphorylcholine polymer-coated stent (n = 598)
Number of subjects: 1197

Group type: COMPARATOR
Intervention: Bare metal stent (n = 599)
Number of subjects: 1197